基于血清miRNA的子宫内膜异位症诊断模型:从发现到验证
本研究在多中心回顾性或前瞻性纳入的364例病理确诊的子宫内膜异位症或良性非内异症妇科疾病患者中,通过RT-qPCR检测23种候选血清miRNA并构建机器学习诊断模型;11种miRNA模型区分内异症与对照的AUC为70.4%、灵敏度75.6%、特异度53.5%、准确率65.8%。
要点
- 11种miRNA诊断模型区分内异症与对照的AUC为70.4%、灵敏度75.6%、特异度53.5%、准确率65.8%。
- 6种miRNA模型识别深部浸润型内异症优于对照,AUC为80.4%、准确率75.9%。
- 模型区分卵巢子宫内膜异位囊肿与对照的AUC为65.8%、准确率62.4%。
核心结论
- 基于miRNA的诊断模型区分内异症患者与对照的准确率为65.8%,灵敏度良好但特异度有限。
- 若在更大队列中验证有效,该模型可作为内异症诊断工具,并因其低假阴性率可能作为筛查工具帮助识别可能患内异症但需进一步评估以确诊的患者。
研究设计与样本
- 多中心研究,从生物样本库回顾性选取或前瞻性纳入共364例病理确诊的子宫内膜异位症或良性非内异症妇科疾病患者。
- 此前已通过高通量RT-qPCR报告67例内异症患者与60例对照的血清miRNA表达模式差异。
- 从手术治疗前采集的血清样本中提取总RNA,通过RT-qPCR评估23种候选诊断miRNA。
- 采用随机森林和逻辑回归算法构建诊断模型,并通过重复交叉验证进行内部验证评估模型性能。
主要发现
- 最佳诊断模型由11种miRNA构建:miR-140-3p、miR-181a-5p、miR-192-5p、miR-22-3p、miR-29a-3p、miR-30b-5p、miR-338-3p、miR-340-5p、miR-342-3p、miR-486-5p和miR-652-3p。
- 该11种miRNA模型的诊断效能为AUC 70.4%、灵敏度75.6%、特异度53.5%、准确率65.8%。
- 由6种miRNA(miR-192-5p、miR-30b-5p、miR-335-5p、miR-338-3p、miR-486-5p、miR-652-3p)构建的模型识别深部浸润型内异症与对照的效果最佳,AUC为80.4%、准确率75.9%。
- 区分卵巢子宫内膜异位囊肿与对照的模型准确率较低,AUC为65.8%、准确率62.4%。
临床怎么用
- 若在更大队列中验证有效,该模型可作为内异症诊断工具,有助于提高该病的早期识别和临床照护。
- 鉴于其低假阴性率,基于miRNA的模型可能作为筛查工具,帮助识别可能患内异症但需进一步评估以确诊的患者。
局限性
- 尽管进行了内部交叉验证,模型仍需在多个中心前瞻性纳入的更大患者队列中测试,以提高准确性和稳健性。
- 该测试也将有助于在真实世界环境中监测模型,可能将基于miRNA的模型与超声等其他诊断工具整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can a serum miRNA signature serve as a potential diagnostic biomarker for endometriosis (END)? SUMMARY ANSWER: A miRNA-based diagnostic model demonstrated an accuracy of 65.8% in distinguishing END patients from control subjects (CTR), demonstrating good sensitivity but limited specificity. WHAT IS KNOWN ALREADY: Existing research has examined the potential utility of circulating miRNAs as biomarkers for END diagnosis, revealing their differential expression between women with END and CTR. Nevertheless, the findings remain conflicting, and at present, neither a single miRNA nor a panel of them has yet been established as a reliable diagnostic test in clinical practice for the management of END. STUDY DESIGN, SIZE, DURATION: We previously reported different miRNA expression patterns in serum samples from 67 END patients and 60 CTR by high-throughput RT-qPCR. In this multicenter study, a total of 364 patients with pathology-confirmed diagnosis of END or a benign non-END gynecological condition were retrospectively selected from a biobank or prospectively enrolled. The aims of the present study were to analyze, in the entire cohort of patients, a set of 23 potential diagnostic miRNAs via RT-qPCR and to create models capable of diagnosing END through cross-validated machine learning algorithms. PARTICIPANTS/MATERIALS, SETTING, METHODS: Total RNA was extracted from serum samples collected before surgical treatment and miRNAs were evaluated by RT-qPCR. Diagnostic models were developed using both the Random Forest and Logistic Regression algorithms. The performance assessment of the various models was derived from internal validation, using repeated cross-validation. MAIN RESULTS AND THE ROLE OF CHANCE: The most effective diagnostic model was constructed with 11 miRNAs: miR-140-3p, miR-181a-5p, miR-192-5p, miR-22-3p, miR-29a-3p, miR-30b-5p, miR-338-3p, miR-340-5p, miR-342-3p, miR-486-5p, and miR-652-3p. The diagnostic efficacy of the model was defined by an AUC of 70.4%, a sensitivity of 75.6%, a specificity of 53.5%, and an accuracy of 65.8%. The model that used six miRNAs (miR-192-5p, miR-30b-5p, miR-335-5p, miR-338-3p, miR-486-5p, miR-652-3p) was the best at identifying deep infiltrating endometriosis compared to the control group, with an AUC of 80.4% and an accuracy of 75.9%. A lower accuracy was achieved by the model differentiating ovarian endometrioma (OMA) from CTR (AUC = 65.8%; accuracy = 62.4%). LARGE SCALE DATA: miRNA expression profiles have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession numbers GSE279435. LIMITATIONS, REASONS FOR CAUTION: Despite the internal cross-validation, the models still need to be tested on larger cohorts of prospectively enrolled patients across several centers to enhance their accuracy and robustness. This testing will also facilitate monitoring the model in a real-world setting, potentially integrating the miRNA-based model with other diagnostic tools, such as ultrasound. WIDER IMPLICATIONS OF THE FINDINGS: If proven effective in larger cohorts, this model could serve as a tool for the diagnosis of END, thereby enhancing early identification and clinical care of this disease. Moreover, given its low false negative rate, the miRNA-based model may be useful as a screening tool to help identify patients who are likely to have END but warrant further evaluation to confirm END diagnosis. STUDY FUNDING/COMPETING INTEREST(S): This research was financed by the Italian Ministry of Health, grant number "LOMBARDIA ENDO-2021-12371946", project title: FREEDOM TRIAL. The authors disclose no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Ravaggi A, Bergamaschi C, Conforti J, et al. Serum miRNA-based diagnostic models for endometriosis: from discovery to validation. Hum Reprod. 2026. PMID: 41270284. doi:10.1093/humrep/deaf221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。